Innovations in Early-Stage Lung Cancer Treatment Offer New Hope

Lung cancer remains the leading cause of cancer-related death in the United States, but a wave of medical innovation is rewriting what’s possible for early-stage patients. At Baptist Health Cancer Care, specialists are employing therapies that deliver new levels of precision and personalization, providing new hope for those diagnosed with this complex disease.

For Ian Bostock, M.D., a thoracic surgical oncologist at Baptist Health Miami Cancer Institute, and Samuel Kareff, M.D., a medical oncologist at the Eugene M. & Christine E. Lynn Cancer Institute at Boca Raton Regional Hospital, part of Baptist Health, the mission is to bring world-class care to patients in South Florida and beyond by combining cutting-edge tools with a deeply collaborative approach.

A New Era in Lung Cancer Detection

The National Cancer Institute estimates 226,650 new cases of lung and bronchus cancer this year, and 124,730 deaths from the disease. It is the third most common type of cancer, after breast cancer and prostate cancer, yet it is the deadliest cancer, with a five-year relative survival rate overall of approximately 29%. For localized early-stage lung cancer, however, the five-year survival rate improves dramatically, to almost 65%.

Dr. Bostock says that thoracic oncology at Baptist Health is “entering a transformative era” and one of the biggest improvements in recent years is in the early detection and diagnosis of lung cancer. To improve accuracy and minimize delays, doctors across Baptist Health Cancer Care now use advanced tools like the MONARCH^™ Platform, the first flexible, robotically assisted platform for bronchoscopy, and special imaging such as endobronchial ultrasound (EBUS).

“These technologies allow us to stage lung cancer with incredible precision,” says Dr. Bostock. “They help us detect cancer at earlier stages, when it’s most treatable, and ultimately improve patient outcomes.”

Robotic bronchoscopy allows for minimally invasive access to nodules that were previously unreachable without surgery. This not only speeds up diagnosis, but also spares patients from more invasive procedures, Dr. Bostock points out.

Reducing Recovery Time with Minimally Invasive Surgery

Once diagnosed, many early-stage patients at Baptist Health are now eligible for robotic-assisted thoracic surgery, which Dr. Bostock says can significantly shorten hospital stays and recovery time.

“Patients often expect to be hospitalized for several days and experience significant post-operative pain but the reality is that most go home in less than 24 hours and are back to normal life much sooner than expected,” he notes.

Minimally invasive surgery offers excellent pain control, a quick return to baseline activity, minimal physical restrictions and reduced reliance on narcotic medications. The use of robotic platforms allows surgeons to perform highly precise procedures with smaller incisions, improving both short- and long-term outcomes.

Lighting the Way with Emerging Technologies

New tools also are being developed to help surgeons see cancer more clearly during surgery. One example is a special agent called abenacianine, a dye that “lights up” cancerous lymph nodes and lung tissue. Baptist Health Cancer Care physicians are paying close attention to how this emerging technology may help patients in the future.

“These types of tools could make it easier for us to remove only what’s needed while still giving patients the best possible results,” says Dr. Bostock. “It’s a promising step toward protecting healthy lung tissue during surgery.”

Expanding Surgical Eligibility with New Evidence

For patients with borderline lung function who may have once been deemed inoperable, new clinical data is opening doors. Recent randomized trials support the use of limited resections, such as wedge resection or segmentectomy (removing a specific section of a lung lobe) for select patients.

“This means we can offer curative surgery to more patients—even those with reduced lung capacity—with outcomes comparable to more extensive surgery,” Dr. Bostock says.

Combining Forces: Surgery, Immunotherapy and Targeted Drugs

Surgical innovation is just one piece of the equation. According to Dr. Kareff, systemic therapies like immunotherapy and targeted treatments are revolutionizing care for both early-stage and advanced lung cancer. These therapies are often integrated as part of trimodality treatment, combining chemotherapy, immunotherapy and surgery to attack cancer from all angles.

“Previously, many patients were not considered surgical candidates,” Dr. Kareff says. “But now, with the addition of immunotherapy and biomarker-guided drugs, we’re seeing remarkable improvements in survival, even in more complex cases.”

Personalized Therapies That Shape the Surgical Plan

Dr. Kareff says today’s systemic therapies are not only more effective, they’re also more personalized. “Modern treatment plans are increasingly based on the patient’s unique tumor biology. We’re seeing shorter courses of treatment, fewer side effects, and much better tolerance overall.”

This level of personalization is helping physicians determine not just if surgery is appropriate, but also when and how to do it for maximum impact.

What’s Next: Individualized, Less Invasive, More Precise Treatments

As both experts look ahead, they see a future where cancer care is even more precise, less invasive and tailored to the patient.

“In the next five to 10 years, we expect improved early detection, more targeted therapies and even individualized cancer vaccines,” Dr. Bostock shares. “And Baptist Health is already preparing for that future.”

Click here for more information about the services available from Baptist Health Cancer Care.

  Ian Bostock, M.D., a thoracic surgical oncologist at Baptist Health Miami Cancer Institute

Samuel Kareff, M.D., a medical oncologist at the Eugene M. & Christine E. Lynn Cancer Institute at Boca Raton Regional Hospital, part of Baptist Health